Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activity to be presented at the American Society of Hematology (ASH) 2026 Annual Meeting --